About cybin inc - CYBN
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
CYBN At a Glance
Cybin, Inc.
100 King Street West
Toronto, Ontario M5X 1C9
| Phone | 1-908-764-8385 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -81,338,634.42 | |
| Sector | Health Technology | Employees | 50 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
CYBN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
CYBN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,626,772.688 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CYBN Liquidity
| Current Ratio | 7.749 |
| Quick Ratio | 7.749 |
| Cash Ratio | 6.304 |
CYBN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -40.379 |
| Return on Equity | -42.75 |
| Return on Total Capital | -49.354 |
| Return on Invested Capital | -42.75 |
CYBN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |